<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854529</url>
  </required_header>
  <id_info>
    <org_study_id>005285</org_study_id>
    <nct_id>NCT00854529</nct_id>
  </id_info>
  <brief_title>Subconjunctival Bevacizumab Effect on Bleb Vascularity</brief_title>
  <official_title>Subconjunctival Bevacizumab Injection for the Prevention of Bleb Vascularization Post Trabeculectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trabeculectomy is an ocular surgery intended to reduce intra-ocular pressure the surgery
      creates a sub-conjunctival filtering bleb which filters aqueous humor fluid out.

      A rather common adverse event of the surgery is increasing vascularity of the conjunctiva
      overlying the bleb. This leads to adherence of the conjunctiva to the sclera and fibrosis and
      finally failure of the bleb (and of the surgery) this study intends to demonstrate that post
      operative subconjunctival bevacizumab injection will reduce incidence of bleb vascularity and
      ultimately, bleb failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      trabeculectomy is an ocular surgery intended to reduce intra-ocular pressure the surgery
      creates a sub-conjunctival filtering bleb which filters aqueous humor fluid out.

      a rather common adverse event of the surgery is increasing vascularity of the conjunctiva
      overlying the bleb. this leads to adherence of the conjunctiva to the sclera and fibrosis and
      finally failure of the bleb (and of the surgery) this study wishes to demonstrate that post
      operative subconjunctival bevacizumab injection will reduce incidence of bleb vascularity and
      ultimately, bleb failure.

      during the study, one study group will be given subconjunctival bevacizumab 1 week after
      surgery, another study group will be given subconjunctival bevacizumab 2 week after surgery,
      and a third group will serve as control and will not receive bevacizumab. if bleb vascularity
      will be diagnosed all patients will be treated according to current guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleb vascularity grading</measure>
    <time_frame>1, 2, 3, 4, 5. 6. montes post operative.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indiana Bleb Appearance Grading Scale (IBAGS)</measure>
    <time_frame>1, 2, 3, 4, 5, 6 months post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>1, 2, 3, 4, 5, 6 months post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for subconjunctival Mitomycin C injection or revision of surgery = yes / no</measure>
    <time_frame>1, 2, 3, 4, 5, 6 months post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bleb Vascularity</condition>
  <condition>Bleb Fibrosis</condition>
  <condition>Trabeculectomy Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>sub-conjunctival injection of 1.25mg Bevacizumab</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post uneventful trabeculectomy with mitomycin c application during surgery

          -  adult

        Exclusion Criteria:

          -  usage of 5-fluorouracil in trabeculectomy

          -  post-operative complications

          -  ischemic heart disease

          -  s/p cerebrovascular accident

          -  allergy to bevacizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>moshe lusky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>omer Y bialer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>rabin medial center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>anat robinson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>moshe lusky, MD</last_name>
    <phone>972-39376113</phone>
    <email>moshel@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>omer Y bialer, MD</last_name>
    <phone>972-39376100</phone>
    <email>omerb2@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah-tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma: a review. Can J Ophthalmol. 2007 Dec;42(6):812-5. Review.</citation>
    <PMID>18026201</PMID>
  </reference>
  <results_reference>
    <citation>Schwartz AL, Van Veldhuisen PC, Gaasterland DE, Ederer F, Sullivan EK, Cyrlin MN. The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. Am J Ophthalmol. 1999 Jan;127(1):8-19.</citation>
    <PMID>9932993</PMID>
  </results_reference>
  <results_reference>
    <citation>Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008 Dec;115(12):2141-2145.e2. doi: 10.1016/j.ophtha.2008.06.009. Epub 2008 Aug 9.</citation>
    <PMID>18692246</PMID>
  </results_reference>
  <results_reference>
    <citation>Coote MA, Ruddle JB, Qin Q, Crowston JG. Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma. 2008 Oct-Nov;17(7):517-8. doi: 10.1097/IJG.0b013e31815f5345.</citation>
    <PMID>18854726</PMID>
  </results_reference>
  <results_reference>
    <citation>Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):148-50.</citation>
    <PMID>16583638</PMID>
  </results_reference>
  <results_reference>
    <citation>Treatment of Failing Blebs with Ranibizumab. Study number NCT00570726. http://clinicaltrials.gov</citation>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>March 2, 2009</last_update_submitted>
  <last_update_submitted_qc>March 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Moshe Lusky / MD</name_title>
    <organization>Rabin Medical Center</organization>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>subconjunctival injection</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>bleb</keyword>
  <keyword>mitomycin c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blister</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

